中国药物经济学2024，Vol.19Issue(10)：14-23,10.DOI:10.12010/j.issn.1673-5846.2024.10.002
甘精胰岛素利司那肽注射液(Ⅱ)治疗中国血糖控制不佳的成人2型糖尿病患者的成本-效果分析
Cost-effectiveness Analysis of iGlarLixi(Ⅱ)in Adult Participants with Suboptimally Controlled Type 2 Diabetes Mellitus in China
刘世蒙 1杨毅 1莫璇 2艾亚萍 2刘君 2袁晓勇 3郭晓蕙3
作者信息
- 1. 复旦大学公共卫生学院,上海 200032
- 2. 艾昆纬企业管理咨询(上海)有限公司真实世界研究,上海 200041
- 3. 北京大学第一医院内分泌科,北京 100034
- 折叠
摘要
Abstract
Objective To evaluate the cost-effectiveness of iGlarLixi(Ⅱ)compared with IDegLira in adult participants with suboptimally controlled type 2 diabetes mellitus(T2DM)in China.Methods IQVIA CORE Diabetes Model(CDM)was used to evaluate the long-term health outcomes and costs of iGlarLixi(Ⅱ)versus IDegLira on basal insulin(BI)suboptimally controlled participants.The clinical parameters of iGlarLixi and IDegLira were obtained from randomized clinical trials conducted in Chinese T2DM participants suboptimally controlled on BI and their relative efficacy was calculated using indirect treatment comparison.Utility and direct medical cost were retrieved from published literature.This study was conducted from a healthcare system perspective,and a lifetime time horizon was used to simulate outcomes in base case analysis.The discount rate of costs and quality-adjusted life years(QALYs)was 5%.The robustness of the findings was assessed by sensitivity analyses.Results Among participants suboptimally controlled on BI,iGlarLixi(Ⅱ)was associated with incremental QALYs of 0.020 and saved ¥7,176 over participants treated with IDegLira.Cost saving of iGlarLixi(Ⅱ)was primarily attributed to significantly lower unit price compared to IDegLira,resulting in a substantial saving of ¥6.14 per day(¥13.44 for iGlarLixi(Ⅱ)vs.¥19.58 for IDegLira).The one-way sensitivity analyses showed that the HbA1c threshold for switching therapy and the time horizon of the study were the key factors affecting the cost-effectiveness among BI suboptimally controlled participants.Probabilistic sensitivity analyses showed that the probabilities of iGlarLixi(Ⅱ)being cost-effective was 88%among BI suboptimally controlled participants,under the threshold of half of gross domestic product per capita in 2023 in China,¥44 679,further confirming the robustness of the base case results.Conclusion Compared with IDegLira,Suboptimally controlled T2DM participants on BI treated with iGlarLixi(Ⅱ)resulted in equivalent QALYs and a cost saving in China.关键词
2型糖尿病/基础胰岛素控制不佳/甘精胰岛素利司那肽注射液(Ⅱ)/德谷胰岛素利拉鲁肽注射液/成本-效果分析Key words
Type 2 diabetes mellitus/Basal insulin suboptimally controlled/iGlarLixi(Ⅱ)/IDegLira/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
刘世蒙,杨毅,莫璇,艾亚萍,刘君,袁晓勇,郭晓蕙..甘精胰岛素利司那肽注射液(Ⅱ)治疗中国血糖控制不佳的成人2型糖尿病患者的成本-效果分析[J].中国药物经济学,2024,19(10):14-23,10.
